BIOMAT Database Logo BIOMAT Database Logo

[Concentration of protease inhibitor alpha 1-antitrypsin in the blood of patients with inflammatory periodontal disease]. 1985

U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010518 Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology) Pericementitis,Pericementitides,Periodontitides
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000515 alpha 1-Antitrypsin Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES. Trypsin Inhibitor, alpha 1-Antitrypsin,alpha 1-Protease Inhibitor,alpha 1-Proteinase Inhibitor,A1PI,Prolastin,Serpin A1,Zemaira,alpha 1 Antiprotease,alpha 1-Antiproteinase,1-Antiproteinase, alpha,Antiprotease, alpha 1,Inhibitor, alpha 1-Protease,Inhibitor, alpha 1-Proteinase,Trypsin Inhibitor, alpha 1 Antitrypsin,alpha 1 Antiproteinase,alpha 1 Antitrypsin,alpha 1 Protease Inhibitor,alpha 1 Proteinase Inhibitor

Related Publications

U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
Alpha 1-antitrypsin (alpha 1-proteinase inhibitor) concentration in the patients with neoplastic disease.
January 1988, Materia medica Polona. Polish journal of medicine and pharmacy,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
The role of alpha 1 protease inhibitor (alpha 1 antitrypsin) in the regulation of immunologic and inflammatory reactions.
August 1980, Australian and New Zealand journal of medicine,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
Alpha-1-antitrypsin (protease inhibitor) phenotypes and longevity.
January 1990, Human heredity,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
Treatment of panniculitis associated with alpha-1-antitrypsin deficiency with alpha-1-protease inhibitor.
January 2003, Acta dermato-venereologica,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
[Substitution therapy in alpha 1-protease inhibitor deficiency (alpha 1-antitrypsin deficiency)].
November 1991, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
Binding of alpha 1 antitrypsin (alpha 1 protease inhibitor) to human lymphocytes.
February 1981, Biochemical and biophysical research communications,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
[Antitrypsin activity of the urine and alpha 1 protease inhibitor].
January 1989, Annales de biologie clinique,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
Alpha-1 antitrypsin protease inhibitor typing in immobilized pH gradients.
January 1993, Annals of clinical and laboratory science,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
Fecal alpha 1-antitrypsin clearance in patients with inflammatory bowel disease.
January 1984, Journal of pediatric gastroenterology and nutrition,
U Skaleric, and P Zajsek, and E Cvetko, and V Zalokar
Liver disease progression in patients with alpha-1 antitrypsin deficiency and protease inhibitor ZZ genotype with or without lung disease.
November 2023, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!